191 related articles for article (PubMed ID: 26339369)
1. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.
Lin Y; Liu F; Fan Y; Qian X; Lang R; Gu F; Gu J; Fu L
Int J Clin Exp Pathol; 2015; 8(7):8028-37. PubMed ID: 26339369
[TBL] [Abstract][Full Text] [Related]
2. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma.
Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
World J Surg Oncol; 2015 Nov; 13():323. PubMed ID: 26607846
[TBL] [Abstract][Full Text] [Related]
4. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
5. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo.
Wang Y; Zhao H; Zhao P; Wang X
Cancer Biomark; 2021; 32(2):221-230. PubMed ID: 34092620
[TBL] [Abstract][Full Text] [Related]
6. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Papadaki C; Sfakianaki M; Lagoudaki E; Giagkas G; Ioannidis G; Trypaki M; Tsakalaki E; Voutsina A; Koutsopoulos A; Mavroudis D; Georgoulias V; Souglakos J
Br J Cancer; 2014 Oct; 111(9):1757-64. PubMed ID: 25233397
[TBL] [Abstract][Full Text] [Related]
7. Significant association of PKM2 and NQO1 proteins with poor prognosis in breast cancer.
Zhu K; Li Y; Deng C; Wang Y; Piao J; Lin Z; Chen L
Pathol Res Pract; 2020 Nov; 216(11):153173. PubMed ID: 32841776
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
9. Expression of XB130 in human ductal breast cancer.
Li J; Sun W; Wei H; Wang X; Li H; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):5300-8. PubMed ID: 26191231
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of pyruvate kinase M2 in breast cancer: A protocol for meta-analysis and bioinformatics validation analysis.
Li H; Yan M; Wu X; Wang Y; Huang L
Medicine (Baltimore); 2021 May; 100(18):e25545. PubMed ID: 33950928
[TBL] [Abstract][Full Text] [Related]
11. The extent of retraction clefts correlates with lymphatic vessel density and VEGF-C expression and predicts nodal metastasis and poor prognosis in early-stage breast carcinoma.
Acs G; Paragh G; Rakosy Z; Laronga C; Zhang PJ
Mod Pathol; 2012 Feb; 25(2):163-77. PubMed ID: 22020194
[TBL] [Abstract][Full Text] [Related]
12. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.
Wang Y; Zhang X; Zhang Y; Zhu Y; Yuan C; Qi B; Zhang W; Wang D; Ding X; Wu H; Cheng J
Cancer Biol Ther; 2015; 16(6):839-45. PubMed ID: 25970228
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer.
Lu W; Cao Y; Zhang Y; Li S; Gao J; Wang XA; Mu J; Hu YP; Jiang L; Dong P; Gong W; Liu Y
Sci Rep; 2016 Jun; 6():26351. PubMed ID: 27283076
[TBL] [Abstract][Full Text] [Related]
16. NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma.
Lv ZD; Zhang L; Liu XP; Jin LY; Dong Q; Li FN; Wang HB; Kong B
Int J Clin Exp Pathol; 2015; 8(4):4015-21. PubMed ID: 26097589
[TBL] [Abstract][Full Text] [Related]
17. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.
Zhao YC; Ni XJ; Li Y; Dai M; Yuan ZX; Zhu YY; Luo CY
World J Surg Oncol; 2012 Aug; 10():165. PubMed ID: 22906075
[TBL] [Abstract][Full Text] [Related]
18. [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
Zhang GH; Yang WT; Zhou XY; Zeng Y; Lu HF; Shi DR
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):155-60. PubMed ID: 17425844
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.
Chen YL; Song JJ; Chen XC; Xu W; Zhi Q; Liu YP; Xu HZ; Pan JS; Ren JL; Guleng B
World J Gastroenterol; 2015 Aug; 21(30):9093-102. PubMed ID: 26290635
[TBL] [Abstract][Full Text] [Related]
20. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
